|Selected news articles which highlight important policy issues.||
News: Weekly Archives
News for the week of 06-02-2006
Latest Drugs Could Shake Up Cancer Market
This Wall Street Journal article explains why we should all give three cheers for the next generation of (so-called) "me-too" drugs. Take, for instance, the current generation of targeted cancer treatments, which have proven successful both for cancer patients and for the companies that make them.
So successful, in fact, that rival companies are rushing to produce similar medicines that will eventually compete with pathbreaking drugs like Herceptin, Gleevec, and Erbitux. Over the long run, the proliferation of drugs with similar mechanisms of action and similar markets will help lower cancer drug prices and offer more treatment alternatives to patients.
The Journal explains that:
Medicine's newest weapons against cancer—drugs that "smart bomb" tumors at their genetic weak points—may soon have a new target: each other.
For firstinclass drugs like Herceptin, it benefits society to pay premium prices that encourages follow–on research—as it is doing now. And, as Herceptin and other biotech drugs go off–patent—and the FDA perfects rules for biogenerics—their prices will drop even more significantly.
|home spotlight commentary research events news about contact links archives|